Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOLERANT Trial: rosuvastatin/ezetimibe vs atorvastatin/ezetimibe after drug-eluting stent implantation
KCT0008362Phase 4Not yet recruiting
- Sponsor
- Dotter
- Start
- Apr 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rosuvastatin, atorvastatin, ezetimibe in coronary arteriosclerosis, cardiac morbidity, hypercholesterolemia, sponsored by Dotter. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
rosuvastatinatorvastatinezetimibe
03
Conditions
coronary arteriosclerosiscardiac morbidityhypercholesterolemia
Beyond the preview
Go deeper on KCT0008362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008362.